BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2016;51:1283-300. [PMID: 27272454 DOI: 10.1038/bmt.2016.141] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Estey EH. Acute myeloid leukemia: 2021 update on risk-stratification and management. Am J Hematol 2020;95:1368-98. [PMID: 32833263 DOI: 10.1002/ajh.25975] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
2 Bondanza A, Ruggeri L, Noviello M, Eikema DJ, Bonini C, Chabannon C, van der Werf S, van Biezen A, de Wreede LC, Crucitti L, Vago L, Merluzzi M, Massei MS, Veelken H, Koc Y, Bader P, Gruhn B, Locatelli F, Ciceri F, Toubert A, Velardi A; EBMT Cell Therapy and Immunobiology Working Party. Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplant 2019;54:867-76. [PMID: 30531916 DOI: 10.1038/s41409-018-0351-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Akaho R, Otsu A, Igarashi A, Aoki Y, Takemura T, Kobayashi S, Ohashi K, Nishimura K. No Evidence for Particular Association Between HLA-Haploidentical Hematopoietic Stem Cell Transplantation and Psychological Distress. Transplant Proc 2019;51:1990-3. [PMID: 31303412 DOI: 10.1016/j.transproceed.2019.03.029] [Reference Citation Analysis]
4 Short NJ, Kantarjian H, Jabbour E, Ravandi F. Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 2018;13:91-9. [DOI: 10.1007/s11899-018-0440-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
5 Mancini N, Greco R, Pasciuta R, Barbanti MC, Pini G, Morrow OB, Morelli M, Vago L, Clementi N, Giglio F, Lupo Stanghellini MT, Forcina A, Infurnari L, Marktel S, Assanelli A, Carrabba M, Bernardi M, Corti C, Burioni R, Peccatori J, Sormani MP, Banfi G, Ciceri F, Clementi M. Enteric Microbiome Markers as Early Predictors of Clinical Outcome in Allogeneic Hematopoietic Stem Cell Transplant: Results of a Prospective Study in Adult Patients. Open Forum Infect Dis 2017;4:ofx215. [PMID: 29226172 DOI: 10.1093/ofid/ofx215] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
6 Forlanini F, Zinter MS, Dvorak CC, Bailey-Olson M, Winestone LE, Shimano KA, Higham CS, Melton A, Chu J, Kharbanda S. Hematopoietic Cell Transplantation-Comorbidity Index Score Is Correlated with Treatment-Related Mortality and Overall Survival following Second Allogeneic Hematopoietic Cell Transplantation in Children. Transplant Cell Ther 2021:S2666-6367(21)01400-7. [PMID: 34848362 DOI: 10.1016/j.jtct.2021.11.015] [Reference Citation Analysis]
7 Gonçalves SEAB, Ribeiro AAF, Hirose EY, Santos FPS, Ferreira FM, Koch LOM, Tanaka M, Souza MS, Souza PMR, Gonçalves TJM, Pereira AZ. Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly. Einstein (Sao Paulo) 2019;17:eAE4340. [PMID: 31116236 DOI: 10.31744/einstein_journal/2019AE4340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Versluis J, Cornelissen JJ. Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR. Seminars in Hematology 2019;56:164-70. [DOI: 10.1053/j.seminhematol.2018.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Salas MQ, Chen S, Lam W, Pasic I, Gerbitz A, Michelis FV, Kim D(H, Al-shaibani Z, Lipton JH, Mattsson J, Kumar R, Viswabandya A, Law AD. Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation 2020;26:1511-9. [DOI: 10.1016/j.bbmt.2020.04.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis., International Conference on Cell-Based Therapies for Multiple Sclerosis., International Conference on Cell-Based Therapies for Multiple Sclerosis. Cell-based therapeutic strategies for multiple sclerosis. Brain 2017;140:2776-96. [PMID: 29053779 DOI: 10.1093/brain/awx154] [Cited by in Crossref: 89] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
11 Hegde PS, Rybicki L, Serafino S, Bernhard L, Corrigan D, Anwer F, Kalaycio M, Sobecks RM, Jagadeesh D, Hill BT, Dean RM, Khouri J, Winter AM, Pohlman B, Majhail NS, Hamilton BK. Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01677-8] [Reference Citation Analysis]
12 Lin RJ, Elko TA, Devlin SM, Shahrokni A, Jakubowski AA, Dahi PB, Perales MA, Tamari R, Shaffer BC, Sauter CS, Papadopoulos EB, Gyurkocza B, Korc-Grodzicki B, Barker JN, Maloy MA, Giralt SA. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplant 2020;55:157-64. [PMID: 31471572 DOI: 10.1038/s41409-019-0654-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
13 Armenian SH, Xiao M, Berano Teh J, Lee B, Chang HA, Mascarenhas K, Lee S, Iukuridze A, Xie JJ, Scott JM, Jones LW, Lennie Wong F, Forman SJ, Nakamura R. Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation. J Natl Cancer Inst 2019;111:837-44. [PMID: 30951603 DOI: 10.1093/jnci/djy231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
14 Orgel E, Auletta JJ. TACL'ing supportive care needs in pediatric early phase clinical trials for acute leukemia: A report from the therapeutic advances in childhood leukemia & lymphoma (TACL) consortium supportive care committee. Pediatr Hematol Oncol 2017;34:409-17. [PMID: 29190169 DOI: 10.1080/08880018.2017.1395936] [Reference Citation Analysis]
15 Cheng GS. Pulmonary Function and Pretransplant Evaluation of the Hematopoietic Cell Transplant Candidate. Clin Chest Med 2017;38:307-16. [PMID: 28477641 DOI: 10.1016/j.ccm.2016.12.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shouval R, Nagler A. From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation. Stem Cell Investig 2017;4:39. [PMID: 28607913 DOI: 10.21037/sci.2017.05.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Ros-Soto J, Snowden JA, Salooja N, Gilleece M, Parker A, Greenfield DM, Anthias C, Alfred A, Harrington A, Peczynski C, Peggs K, Madrigal A, Basak GW, Schoemans H; Transplant Complications Working Party of the EBMT. Current Practice in Vitamin D Management in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019;25:2079-85. [PMID: 31229642 DOI: 10.1016/j.bbmt.2019.06.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jia S, Qiao R, Xiao Y, Qin D, Zhao W, Zhao Y, Liu X, Dong B. Prognostic value of sarcopenia in survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: a systematic review and meta-analysis. Support Care Cancer 2020;28:3533-42. [PMID: 32090284 DOI: 10.1007/s00520-020-05359-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol 2018;93:1267-91. [PMID: 30328165 DOI: 10.1002/ajh.25214] [Cited by in Crossref: 167] [Cited by in F6Publishing: 148] [Article Influence: 41.8] [Reference Citation Analysis]
20 Versluis J, Kalin B, Zeijlemaker W, Passweg J, Graux C, Manz MG, Vekemans M, Biemond BJ, Legdeur MJ, Kooy MVM, de Weerdt O, Wijermans PW, Hoogendoorn M, Bargetzi MJ, Kuball J, Schouten HC, van der Velden VH, Janssen JJ, Pabst T, Lowenberg B, Jongen-lavrencic M, Schuurhuis GJ, Ossenkoppele G, Cornelissen JJ. Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. JCO Precision Oncology 2017. [DOI: 10.1200/po.17.00078] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
21 Wu P, Liang W, Chen X, Chen L, Yang X, Yan Z, Wang W. Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019;98:e14474. [PMID: 30813150 DOI: 10.1097/MD.0000000000014474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Greco R, Labopin M, Badoglio M, Veys P, Furtado Silva JM, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Saccardi R, Lankester A, Alexander T, Gennery AR, Bader P, Farge D, Snowden JA. Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Front Immunol 2019;10:1570. [PMID: 31333680 DOI: 10.3389/fimmu.2019.01570] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
23 Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-47. [PMID: 27895058 DOI: 10.1182/blood-2016-08-733196] [Cited by in Crossref: 2119] [Cited by in F6Publishing: 2076] [Article Influence: 353.2] [Reference Citation Analysis]
24 Dhawale T, Steuten LM, Deeg HJ. Uncertainty of Physicians and Patients in Medical Decision Making. Biology of Blood and Marrow Transplantation 2017;23:865-9. [DOI: 10.1016/j.bbmt.2017.03.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
25 Aladağ E, Demiroğlu H, Büyükaşık Y, Göker H. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Turk J Haematol 2021;38:138-44. [PMID: 32539316 DOI: 10.4274/tjh.galenos.2020.2020.0178] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, Kordelas L, Beelen D, Gooley T, Sandmaier BM, Sorror M, Zeisbrich M, Radujkovic A, Dreger P, Penack O. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2020;55:553-61. [PMID: 31558788 DOI: 10.1038/s41409-019-0703-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
27 Rodrigues M, de Souza PMR, de Oliveira Muniz Koch L, Hamerschlak N. The use of comprehensive geriatric assessment in older patients before allologeneic hematopoietic stem cell transplantation: A cross-sectional study. J Geriatr Oncol 2020;11:100-6. [PMID: 31230926 DOI: 10.1016/j.jgo.2019.05.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
28 Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. The Lancet 2018;392:593-606. [DOI: 10.1016/s0140-6736(18)31041-9] [Cited by in Crossref: 167] [Cited by in F6Publishing: 102] [Article Influence: 41.8] [Reference Citation Analysis]
29 Penack O, Peczynski C, van der Werf S, Finke J, Ganser A, Schoemans H, Pavlu J, Niittyvuopio R, Schroyens W, Kaynar L, Blau IW, van der Velden WJFM, Sierra J, Cortelezzi A, Wulf G, Turlure P, Rovira M, Ozkurt Z, Pascual-Cascon MJ, Moreira MC, Clausen J, Greinix H, Duarte RF, Basak GW. Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. Front Immunol 2020;11:586. [PMID: 32351502 DOI: 10.3389/fimmu.2020.00586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lin RJ, Michaud L, Lobaugh SM, Nakajima R, Mauguen A, Elko TA, Ruiz JD, Maloy MA, Sauter CS, Dahi PB, Perales MA, Shah GL, Castillo Flores N, Sanchez-Escamilla M, Tomas AA, San Segundo LY, Cho C, Politikos I, Kim SJ, Korc-Grodzicki B, Devlin SM, Scordo M, Schöder H, Giralt SA, Hamlin PA. The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. Leuk Lymphoma 2020;61:1833-41. [PMID: 32228298 DOI: 10.1080/10428194.2020.1742909] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Elsawy M, Storer BE, Milano F, Sandmaier BM, Delaney C, Salit RB, Rashad AH, Woolfrey AE, Appelbaum FR, Storb R, Sorror ML. Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. Biol Blood Marrow Transplant 2019;25:1045-52. [PMID: 30500442 DOI: 10.1016/j.bbmt.2018.11.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
32 Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E2856. [PMID: 33023002 DOI: 10.3390/cancers12102856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shibasaki Y, Suwabe T, Katagiri T, Tanaka T, Ushiki T, Fuse K, Sato N, Yano T, Kuroha T, Hashimoto S, Narita M, Furukawa T, Sone H, Masuko M. Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. Int J Hematol 2018;108:282-9. [DOI: 10.1007/s12185-018-2463-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Bartoszko J, Panzarella T, McNamara CJ, Lau A, Schimmer AD, Schuh AC, Sibai H, Maze D, Yee KWL, Devlin R, Gupta V. Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. Clin Lymphoma Myeloma Leuk 2017;17:774-81. [PMID: 28711573 DOI: 10.1016/j.clml.2017.06.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
35 Maertens J, Logan AC, Jang J, Long G, Tang JL, Hwang WYK, Koh LP, Chemaly R, Gerbitz A, Winkler J, Yeh SP, Hiemenz J, Christoph S, Lee DG, Wang PN, Holler E, Mielke S, Akard L, Yeo A, Ramachandra S, Smith K, Pertel P, Segal F. Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. Antimicrob Agents Chemother 2020;64:e02467-19. [PMID: 32015031 DOI: 10.1128/AAC.02467-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
36 Kennedy VE, Muffly LS. Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. Expert Review of Hematology 2019;12:99-106. [DOI: 10.1080/17474086.2019.1568236] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Armenian SH, Iukuridze A, Teh JB, Mascarenhas K, Herrera A, McCune JS, Zain JM, Mostoufi-Moab S, McCormack S, Slavin TP, Scott JM, Jones LW, Sun CL, Forman SJ, Wong FL, Nakamura R. Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. J Cachexia Sarcopenia Muscle 2020;11:962-72. [PMID: 32212263 DOI: 10.1002/jcsm.12570] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Mascarenhas K, Teh JB, Peng K, Kim H, Sy A, Forman SJ, Wong FL, Nakamura R, Dadwal SS, Armenian SH. Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2020;55:1662-4. [PMID: 31616064 DOI: 10.1038/s41409-019-0717-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Hegde P, Rybicki L, Serafino S, Ferraro C, Kalaycio M, Sobecks R, Gerds AT, Caroniti S, Corrigan D, Giannetti K, Elberson J, Hodgeman B, Starn J, Dabney J, McLellan L, Majhail NS, Hamilton BK. Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2021. [PMID: 34628474 DOI: 10.1038/s41409-021-01491-8] [Reference Citation Analysis]
40 Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, Fretham C, Jacobsohn DA, Loren AW, Kurtzberg J, Martinez CA, Mineishi S, Nelson AS, Woolfrey A, Pasquini MC, Sorror ML. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. Blood 2019;133:754-62. [PMID: 30545834 DOI: 10.1182/blood-2018-09-876284] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
41 Limbach M, Kuehl R, Dreger P, Luft T, Rosenberger F, Kleindienst N, Friedmann-Bette B, Bondong A, Bohus M, Wiskemann J. Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation. Support Care Cancer 2021;29:359-67. [PMID: 32367227 DOI: 10.1007/s00520-020-05485-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Salas M, Henderson M, Sundararajan M, Tu N, Islam Z, Ebeid M, Horne L. Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review. PLoS One 2021;16:e0252925. [PMID: 34143813 DOI: 10.1371/journal.pone.0252925] [Reference Citation Analysis]
43 Barth D, Singleton M, Monohan G, McClune B, Adams V. Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population. Cell Transplant 2022;31:9636897221080385. [PMID: 35225031 DOI: 10.1177/09636897221080385] [Reference Citation Analysis]
44 Chen J, Yang L, Fan Y, Xu Y, Han Y, Tang X, Qiu H, Fu C, Miao M, Chen F, Wu D. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission. Biology of Blood and Marrow Transplantation 2018;24:779-88. [DOI: 10.1016/j.bbmt.2017.12.796] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]